Get started

Roche

Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above, we aim at least to revisit the old high, up to an Wave 5 extension. This scenario would place us at a level of $552, marking a 120% increase from our entry point, with a stop-loss set at 6.5%, resulting in a risk-to-reward ratio of 18.65%, which is phenomenal if it materializes. We believe the risk-reward ratio is so favorable that we must proceed with this trade. As long as we don't fall below the invalidation zone, i.e., the level of Wave (1), we continue to anticipate that Wave 4 holds. As mentioned, it wouldn't make sense for us to fall below the 61.8% level for Wave (4), as statistically, there's little to gain beyond that point.
SIX:ROLong
by stromm_by_wmc
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is testing the trendline connecting the lows in 2003 and 2011. If you live in the US, you might want to have some exposure to Swiss assets (CHF or stocks) and Gold & silver. The US dollar is losing value against the Swiss Francs in the long term. Otherwise, Roche stock price must hold up at the current support zone , otherwise, we are open for a 30+% drop to the next support zone, which will be of course, an absolute bargain. Also, it looks like the previous turnovers from the lows were always accompanied by the MA36 and MA12 crossing (MA12 over MA36) However, we do not have it here yet. So, let's keep an eye on it. That's it. 1PERCENT
SIX:ROGLong
by RVD_1PERCENT
PIRS Pieris Pharmaceuticals a Sleeping Giant ??PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche. AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments Servier 40Mil upfront payment and 447Mil potential milestone payments So a best case scenario company with 9Bil Revenue PIRS Pieris Pharmaceuticals Market Cap is only 254Mil now!!! On 4/26/2021 HC Wainwright Brokerage set up a price target for PIRS at $9.00 per share. What do you think it`s the real upside potential of Pieris Pharmaceuticals?? PIRS was on my private calls list since 3.42usd.
PLong
by TopgOptions
5
Roche reversalRoche making higher lows inside a descending broadening wedgem, while showing signs of accumulation with a sell wall at 326.85$. The bullish engulfing candles on Jan 11 and the Marubozu on Feb 4 show that the demand for this asset is high at the previous Peak back in December 2014. The fact that there is also MACD hidden bullish divergence on the daily and the monthly strengthens the argument for a reversal and a break out of this structure in the coming weeks or months.
SIX:ROGLong
by luyestefan
Vaccibody / Genentech deal closed #biotechVaccibody announces the closing of the worldwide license and collaboration agreement with Genentech All antitrust contingencies required to close the agreement with Genentech, regarding the development of individualized neoantigen cancer vaccines, have been satisfied Oslo, Norway, November 06, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the closing of its exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, following expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended. As announced on October 1, 2020, Vaccibody and Genentech have entered into an agreement for the development and commercialization of DNA-based individualized neoantigen vaccines. With the expiration of the HSR Act waiting period, the agreement is now effective and Vaccibody is entitled to receive USD 200 million in initial upfront and near-term payments. Under the terms of the agreement, in addition to the USD 200 million in initial upfront and near-term payments that Vaccibody is entitled to receive, Vaccibody will be eligible to receive up to a further USD 515 million in potential payments and milestones, plus low double-digit tiered royalties on sales of commercialized products arising from the partnership. Through this partnership, Genentech and Vaccibody will progress Vaccibody’s investigational product candidate, VB10.NEO, into clinical trials in the U.S. and in Europe. Following completion of a planned Phase 1b trial, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities. About Vaccibody Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is using the Vaccibody technology to generate best-in-class therapeutics against cancers and infectious diseases with a high unmet medical need. Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody’s vaccines specifically targets antigens to Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. Vaccibody has collaborations with Roche and Genentech, and Nektar Therapeutics and will pursue further collaborations and strategic partnerships to maximize the value of its technology platform. Vaccibody’s shares are traded on Merkur Market, a trading platform operated and wholly owned by Oslo Børs ASA, the Oslo Stock Exchange. Further information about the Company may be found at www.vaccibody.com
VLong
by savepiginvest
99.9% down from ATH. A play for biotech catalyst investorsRegenerative medicine company developing novel placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.
P
by warrenhochfeld
1
Monthly depressing stocks reviewI have been looking at stocks a little bit on the side, once in a while, for a long time. Now I think I have to really get into it, the way I do things (the RIGHT way is the name I think), I just look for good opportunities, I don't focus on just a few and try to force money out of the market (lol). And with currencies, well... This: Whereas stocks are always trending, their problem is they are quite correlated, but they are not all 100% correlated. And with a buy only, odds are on our side, they tend to go up all the time, and risk to reward is assymetric (a gain of 50% is a loss of 33% way easier to go up 90% than down 90%, impossible to go down 101%, possible to go up... does not make a difference with 1% moves, but when we get at 10% and more, it makes a difference, you stop loss can have the same RR as usual but be super far, or be at the same distance as usual but you get a RR of 2 rather than the usual 1.5 for example). Plus biggest possible loss is 100%... That's pretty nice. Go all in? Can't lose more than this. On a general note, I think FAANG stocks topped and the bubble popped, but the stock market in general could keep going up. It's expensive, it's dumb to invest now, but it was dumb in 1929 and 1999 too. Every one that knows anything can see what a bubble this is, but dumb money is just that. They're irrational, they're stupid, and they can push the price 100-150% like in 1929 and 1999, because it all explodes down. Stocks I am watching that I might trade in the next month or 2 - I filtered some just because it gets too redundant (correlation): Philip Morris managed to recover, it retraced at the previous swing high (92.74/92.69) and that downtrend line, but it could just be cooling off before breaking. I have a watchlist of 90 but they're all just going up or moving randomly. Maybe I should look at penny stocks. Oh this is depressing. I simply do not want to buy when indices are at all time high and P/E ratios are at 1929 & 1999 levels and all that... So going to miss out and have to wait... Can we get a new crypto bubble? That was really awesome. I believe people that fail other than being simply not cut out for this / really bad fail, they probably overtrade or just look for opportunities when there aren't any, or the macro situation is not that great... If the stock market as a whole rallies some more well I'll look for buys but nothing long term. In the meantime, just going to have to find other ways to make money. That's all I got I just don't know other ways to trade. Maybe I'll have to spend all my day in front of the screen and scalp I do have strategies for this but don't want to ... :( I find it kind of funny I find it kind of sad... Hello darkness my old friend...
NASDAQ:NFLX
by MrRenev
1
Time to go long on PIRS, very long.The has been absolutely no fundamental change to this bio company that has multiple big pharma partners. Yet due to the overall biotech downturn NASDAQ:PIRS was hit pretty hard. This presents a true 10 bagger opportunity , and Im not even remotely stretching the truth. The technicals show you why right now is the PERFECT time to buy. A little due diligence will show you why its a must hold in 2016. As you will find here --> there is plenty in the pipeline, both propietary and partnered. And when your partners are this strong, its hard to fail.
PLong
by WholeLottaBull